Wang Haoran, Ma Li, Su Weiran, Liu Yangruoyu, Xie Ning, Liu Jun
Department of Orthopaedics, Tongji Hospital Affiliated to Tongji University, Shanghai 200065, P.R. China.
Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, P.R. China.
Int J Mol Med. 2025 Mar;55(3). doi: 10.3892/ijmm.2025.5489. Epub 2025 Jan 24.
Activation of inflammasomes is the activation of inflammation‑related caspase mediated by the assembly signal of multi‑protein complex and the maturity of inflammatory factors, such as IL‑1β and IL‑18. Among them, the Nod‑like receptor family pyrin domain containing 3 (NLRP3) inflammasome is the most thoroughly studied type of inflammatory corpuscle at present, which is involved in the occurrence and development of numerous human diseases. Therefore, targeting the NLRP3 inflammasome has become the focus of drug development for related diseases. In this paper, the research progress of the NLRP3 inflammasome in recent years is summarized, including the activation and regulation of NLRP3 and its association with diseases. A deep understanding of the regulatory mechanism of NLRP3 will be helpful to the discovery of new drug targets and the development of therapeutic drugs.
炎性小体的激活是由多蛋白复合物的组装信号介导的炎症相关半胱天冬酶的激活以及炎性因子(如IL-1β和IL-18)的成熟。其中,含NOD样受体家族吡啉结构域3(NLRP3)炎性小体是目前研究最为深入的炎性小体类型,其参与众多人类疾病的发生发展。因此,靶向NLRP3炎性小体已成为相关疾病药物研发的焦点。本文综述了近年来NLRP3炎性小体的研究进展,包括NLRP3的激活与调控及其与疾病的关联。深入了解NLRP3的调控机制将有助于发现新的药物靶点和开发治疗药物。